Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, discusses the results from a Phase III trial comparing the efficacy of momelotinib versus ruxolitinib in participants with myelofibrosis (MF) who have not yet received treatment with a JAK inhibitor (NCT01969838). Two major unmet needs of patients with MF are improving anaemia and splenomegaly, as stated by Dr. Mesa, and momelotinib has been shown to be superior to ruxolitinib in improving these conditions, although the overall results are mixed. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.